Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of July 2026 for Haleon Plc, a consumer health company focused on everyday health across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The filing discloses capital structure and voting rights data as of June 30, 2026.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report is limited to corporate governance and capital structure disclosures.
Material Changes
No material financial changes versus prior periods are disclosed in this filing. The document serves as a notification of the total number of issued shares and voting rights as of the end of the previous quarter.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It includes a standard description of the company's portfolio and brands, such as Advil, Centrum, and Sensodyne.
Key Facts for Investors
- Total Issued Shares: 8,820,906,422 ordinary shares of £0.01 each as of June 30, 2026.
- Treasury Shares: 12,006,714 shares held in treasury.
- Voting Rights: 8,808,899,708 ordinary shares carry voting rights.
- Notification Threshold: Shareholders must use the voting share count (8,808,899,708) as the denominator for calculating notifiable interests under FCA rules.
- Contact: Notifiable interests should be sent to company.secretary@haleon.com.